FNY Investment Advisers’s Pacific Biosciences PACB Stock Holding History

FNY Investment Advisers’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$16K	Hold	10,000	–	–	0.01%	562
2026 Q1	$13K	Hold	10,000	–	–	0.01%	522
2025 Q4	$18K	Sell	10,000 -10,000	-50%	-$19.2K	0.01%	582
2025 Q3	$25K	Hold	20,000	–	–	0.01%	647
2025 Q2	$24K	Hold	20,000	–	–	0.01%	530
2025 Q1	$23K	Sell	20,000 -5,000	-20%	-$7.67K	0.01%	381
2024 Q4	$45K	Buy	+25,000	New	+$48.8K	0.02%	342
2021 Q1	–	Sell	-38,600	Closed	-$1M	–	960
2020 Q4	$1M	Buy	+38,600	New	+$656K	0.27%	94
2020 Q1	–	Sell	-3,935	Closed	-$20K	–	719
2019 Q4	$20K	Buy	3,935 +100	+3%	+$508	0.01%	579
2019 Q3	$19K	Sell	3,835 -7,365	-66%	-$41.2K	0.01%	531
2019 Q2	$67K	Buy	11,200 +7,600	+211%	+$53.3K	0.02%	336
2019 Q1	$26K	Buy	3,600 +4	+0.1%	+$29	0.01%	380
2018 Q4	$26K	Buy	+3,596	New	+$22.8K	0.01%	331

Other funds holding PACB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

FNY Investment Advisers's PACB Position: Q2 2026 in Review

FNY Investment Advisers held its Pacific Biosciences (PACB) position steady in Q2 2026 at 10,000 shares worth $16K. The position accounts for 0.01% of the portfolio, ranked #562.

FNY Investment Advisers first reported a position in PACB in Q4 2018 and has held it in 13 quarters since. The position peaked at $1M in Q4 2020. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

FNY Investment Advisers held 10,000 shares of Pacific Biosciences worth $16K as of Q2 2026.
FNY Investment Advisers left its Pacific Biosciences share count unchanged in Q2 2026.
Pacific Biosciences made up 0.01% of FNY Investment Advisers's portfolio in Q2 2026, its #562 holding.
FNY Investment Advisers first reported a position in Pacific Biosciences in Q4 2018 and has held it in 13 quarters since.
FNY Investment Advisers's Pacific Biosciences position peaked at $1M in Q4 2020.
223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on FNY Investment Advisers's 13F filing for Q2 2026, filed 8 Jul 2026.